Stay updated on Atezolizumab Combo in Esophageal Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab Combo in Esophageal Carcinoma Clinical Trial page.

Latest updates to the Atezolizumab Combo in Esophageal Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check9 days agoChange DetectedA site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” in some content. It appears above the study page’s 403 error.SummaryDifference1%

- Check16 days agoChange DetectedThe ClinicalTrials.gov study page remains a 403 Forbidden error page; its footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check23 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1 while the study record page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check44 days agoChange DetectedThe page now renders a 403 Forbidden error, replacing the usual study record content with an error screen and preventing access to the trial's details on that page.SummaryDifference18%

- Check65 days agoChange DetectedThe page now states there are 67 participating locations. It also updates the outcomes section to specify IRF-assessed PFS and OS with defined criteria, adds CRS grading and quality-of-life/AE measures, and introduces an IPD data-sharing plan with related documents.SummaryDifference2%

Stay in the know with updates to Atezolizumab Combo in Esophageal Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab Combo in Esophageal Carcinoma Clinical Trial page.